Dr. Matthew Tuck is an internist at the Washington DC VA Medical Center and lead site investigator for the African American Cardiovascular Pharmacogenomics Consortium (ACCOuNT). (Photo by Mike Richman)

Imagine a scenario in which a patient is at risk for blood clots. His doctor checks the patient’s genetic makeup and decides on a particular blood thinner, one of several available. The drug works as expected, improving blood flow and reducing the chances of heart attack, stroke, or death.

Such an approach to prescribing drugs is becoming more and more commonplace. In fact, it’s part of a revolution in medicine called pharmacogenomics, the study of how genes influence the way a person responds to drugs.

But are all patients benefiting?

Dr. Matthew Tuck, an internist at the Washington DC VA Medical Center, is concerned that African Americans have been largely excluded from this revolution, especially when it comes to drugs for heart diseases. He’s a member of the African American Cardiovascular Pharmacogenomics Consortium (ACCOuNT). It was created in 2016 to advance the field of pharmacogenomics, with an emphasis on the cardiovascular health of African Americans.

“Most studies on pharmacogenomics have been conducted nearly exclusively on Americans of European descent, leading to health disparities,” says Tuck, who is also an associate professor at The George Washington University in Washington, D.C., and the Uniformed Services University of the Health Sciences in Maryland. “Also, studies have largely overlooked differences in adverse reactions to drugs, according to ethnicity.”

The goal of pharmacogenomics is “making sure the right person receives the right drug at the right dose,” says Tuck. “In an ideal situation, a health care provider would know whether a certain drug would be appropriate for a person before it’s prescribed.”

Currently, more than 500 African Americans are enrolled in the ACCOuNT study. About 30 percent are from the Washington VA, making it the largest recruiting site to date.

The ultimate goal is to enroll at least 1,500 African Americans. They are sharing their genetic information through blood samples for what Tuck says will be the largest bank of pharmacogenomic data that is focused solely on African Americans.

To read more about this project, visit VA Research Currents.

To learn more about VA research in genomics or health equity, visit the topic pages section of the VA Research website.

Share this story

Published on May. 31, 2019

Estimated reading time is 1.9 min.

Views to date: 162

More Stories

  • New genetic research discoveries may one day help doctors better screen Veterans at risk of suicide and prevent it in the first place.

  • Greg Amira, Purple Heart Iraq Veteran and 9/11 survivor, became the 900,000th Veteran to join the Million Veteran Program.

  • A VA study has found that Pharmacogenomic, or genetic testing, can help providers avoid prescribing antidepressant medications that may have undesirable outcomes.